domingo, 12 de febrero de 2017

Targeted pharmacotherapy after somatic cancer mutation screening. - PubMed - NCBI

Version 2. 2016 Jun 30 [revised 2016 Sep 20];5:1551. doi: 10.12688/f1000research.9040.2. eCollection 2016.

Targeted pharmacotherapy after somatic cancer mutation screening.

Polasek TM1, Ambler K2, Scott HS2, Sorich MJ1, Kaub PA2, Rowland A1, Wiese MD3, Kichenadasse G4.

Author information

Abstract

Many patients with solid tumours are treated with targeted pharmacotherapy based on the results of genetic testing ('precision medicine'). This study investigated the use of targeted drugs after OncoFOCUS™+ KIT screening in patients with malignant melanoma, non-small cell lung cancer and metastatic colorectal cancer, and then audited the results against the National Comprehensive Cancer Network (NCCN) guidelines. Patients who were not indicated for targeted pharmacotherapy did not receive such treatment (99%, 100/101). Of the patients indicated for targeted drugs, 79% (33/42) received treatment according to NCCN guidelines. In 48% (20/42) of these patients the results from OncoFOCUS™+ KIT screening were required for targeted drug selection, with the remaining 52% (22/42) prescribed drugs independent of the screening results for various reasons. This study highlights the growing importance of precision medicine approaches in directing pharmacotherapy in medical oncology.

KEYWORDS:

: targeted pharmacotherapy; bevacizumab; dabrafenib erlotinib; malignant melanoma; metastatic colorectal cancer; non-small cell lung cancer; oncology; precision medicine